Raised PSA (prostate-specific antigen) with breast cancer linked to poor outcome
This article was originally published in Clinica
Plasma levels of prostate-specific antigen (PSA) may predict the outcome for breast cancer patients treated with megestrol acetate, says an international group of cancer researchers. PSA is an established marker of prostate cancer but its presence in minute amounts in female plasma was first noted in 1995.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.